Zeba N. Singh

1.6k total citations
54 papers, 984 citations indexed

About

Zeba N. Singh is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Zeba N. Singh has authored 54 papers receiving a total of 984 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 18 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Zeba N. Singh's work include Multiple Myeloma Research and Treatments (15 papers), Acute Myeloid Leukemia Research (13 papers) and Protein Degradation and Inhibitors (8 papers). Zeba N. Singh is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Acute Myeloid Leukemia Research (13 papers) and Protein Degradation and Inhibitors (8 papers). Zeba N. Singh collaborates with scholars based in United States and India. Zeba N. Singh's co-authors include Frits van Rhee, Ashraf Badros, Bart Barlogie, Susann Szmania, Katie Stone, Aaron P. Rapoport, Mehmet H. Kocoglu, Cameron Dell, Olga Goloubeva and Maria R. Baer and has published in prestigious journals such as Blood, Cancer Cell and Journal of the American Academy of Dermatology.

In The Last Decade

Zeba N. Singh

48 papers receiving 966 citations

Peers

Zeba N. Singh
Mojtaba Akhtari United States
Kazutaka Sunami Japan
Alison R. Sehgal United States
Benoît Tessoulin France
Prajwal Boddu United States
Tomoaki Fujisaki Japan
Abdul Hamid Bazarbachi United States
Zaid Al‐Kadhimi United States
Carolina Schinke United States
Axel Schulenburg Austria
Mojtaba Akhtari United States
Zeba N. Singh
Citations per year, relative to Zeba N. Singh Zeba N. Singh (= 1×) peers Mojtaba Akhtari

Countries citing papers authored by Zeba N. Singh

Since Specialization
Citations

This map shows the geographic impact of Zeba N. Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zeba N. Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zeba N. Singh more than expected).

Fields of papers citing papers by Zeba N. Singh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zeba N. Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zeba N. Singh. The network helps show where Zeba N. Singh may publish in the future.

Co-authorship network of co-authors of Zeba N. Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Zeba N. Singh. A scholar is included among the top collaborators of Zeba N. Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zeba N. Singh. Zeba N. Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kallen, Michael E., et al.. (2023). Macrophage activation syndrome after granulocyte colony‐stimulating factor in a patient with systemic lupus erythematosus. British Journal of Haematology. 204(3). 747–748.
2.
Singh, Zeba N., et al.. (2023). B-acute lymphoblastic leukemia with eosinophilic inclusions. Blood. 141(13). 1645–1645.
3.
Koka, Rima, Michael E. Kallen, Aaron P. Rapoport, et al.. (2023). A Subset of Classical Hodgkin Lymphoma Cases Demonstrate CD19 Expression on Hodgkin Reed-Sternberg Cells By Immunohistochemistry. Blood. 142(Supplement 1). 6125–6125. 1 indexed citations
4.
Kallen, Michael E., Rima Koka, Zeba N. Singh, et al.. (2022). Therapy-related B-lymphoblastic leukemia after multiple myeloma. Leukemia Research Reports. 18. 100358–100358. 4 indexed citations
5.
Soleimani, Arshia, et al.. (2020). Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax. Clinical Lymphoma Myeloma & Leukemia. 20(9). e556–e559. 2 indexed citations
6.
Duong, Vu H., Kebede H. Begna, Kendra Sweet, et al.. (2020). Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. Annals of Hematology. 99(9). 2119–2124. 6 indexed citations
7.
Chaer, Firas El, Noa G. Holtzman, Edward A. Sausville, et al.. (2019). Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. Acta Haematologica. 141(2). 107–110. 14 indexed citations
8.
Singh, Zeba N., Vu H. Duong, Rima Koka, et al.. (2018). High-risk acute promyelocytic leukemia with unusual T/myeloid immunophenotype successfully treated with ATRA and arsenic trioxide-based regimen. Journal of Hematopathology. 11(3). 67–74. 5 indexed citations
9.
Badros, Ashraf, Elizabeth Hyjek, Ning Ma, et al.. (2017). Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 130(10). 1189–1197. 146 indexed citations
10.
11.
Chaer, Firas El, Noa G. Holtzman, Neil C. Porter, et al.. (2017). Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL. Bone Marrow Transplantation. 52(11). 1583–1584. 6 indexed citations
12.
Muvarak, Nidal, Limin Xia, Carine Robert, et al.. (2016). Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer. Cancer Cell. 30(4). 637–650. 144 indexed citations
13.
14.
Hiatt, Kim M., et al.. (2015). Acute alopecia with underlying pruritic erythema. Journal of the American Academy of Dermatology. 73(5). 893–894. 1 indexed citations
15.
Usmani, Saad Z., Bijay Nair, Pingping Qu, et al.. (2012). Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 26(11). 2398–2405. 45 indexed citations
16.
Singh, Zeba N., Ginell R. Post, Elias Kiwan, & Anne‐Marie Maddox. (2011). Cytopenia, Dysplasia, and Monocytosis: A Precursor To Chronic Myelomonocytic Leukemia or a Distinct Subgroup? Case Reports and Review of Literature. Clinical Lymphoma Myeloma & Leukemia. 11(3). 293–297. 6 indexed citations
17.
Singh, Zeba N., Dinesh Rakheja, Tribhuvan Pal Yadav, & Durjoy K. Shome. (2005). Infection-associated haemophagocytosis: the tropical spectrum. Clinical & Laboratory Haematology. 27(5). 312–315. 33 indexed citations
18.
Singh, Zeba N. & Amit K. Dinda. (1998). Renal dysplasia: An autopsy study of associated congential malformations. The Indian Journal of Pediatrics. 65(2). 311–318. 7 indexed citations
19.
Wani, N. A., et al.. (1977). Primary gastric tuberculosis.. Indian Journal of Tuberculosis. 24(3). 133–134. 1 indexed citations
20.
Singh, Zeba N., et al.. (1977). Evaluation of bacteria and biliary tract diseases.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(10). 564–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mojtaba Akhtari Breakdown of academic impact, for papers by Kazutaka Sunami Breakdown of academic impact, for papers by Alison R. Sehgal Breakdown of academic impact, for papers by Benoît Tessoulin Breakdown of academic impact, for papers by Prajwal Boddu Breakdown of academic impact, for papers by Tomoaki Fujisaki Breakdown of academic impact, for papers by Abdul Hamid Bazarbachi Breakdown of academic impact, for papers by Zaid Al‐Kadhimi Breakdown of academic impact, for papers by Carolina Schinke Breakdown of academic impact, for papers by Axel Schulenburg
Rankless by CCL
2026